Company Profile
Molecular Partners Stock Price, News & Analysis
- Ticker:
- MOLN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
4.00 USD (+2.96%)
Close
Last updated: July 27, 2026
147M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, MOLN closed up 2.96% at $4.00. No new same-company headline was identified in the current news window.
Company overview
Business overview
Molecular Partners is a biotechnology company focused on designed protein therapeutics and oncology. Its platform is built around engineered binding proteins that can attack disease biology in new ways.
Geographic Base and Sector Classification
Headquartered in Switzerland and listed on NASDAQ as an ADR, Molecular Partners has a global biotech profile.
Business Model Characteristics
The business depends on platform validation, clinical progress, and the ability to create differentiated oncology assets.
Position Within the Biotechnology Landscape
Molecular Partners is a platform protein-therapeutics name with strong sensitivity to translational data.
Future catalysts
Molecular Partners’s catalysts are its DARPin platform and oncology partnerships, plus any update that shows the platform can still produce meaningful partnering value. The company needs external validation to keep the story moving.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Molecular Partners (MOLN)?
Molecular Partners (MOLN) most recently closed at 4.00 USD, a +2.96% move versus the previous session.
What is the market cap of Molecular Partners (MOLN)?
Molecular Partners currently has a market capitalization of 147M USD on BioPharmSignal.
What does Molecular Partners do?
Molecular Partners is a biotechnology company focused on designed protein therapeutics and oncology. Its platform is built around engineered binding proteins that can attack disease biology in new ways.
On which exchange is MOLN stock listed?
Molecular Partners (MOLN) is associated with NASDAQ, Switzerland, Biopharma.
What is Molecular?
Molecular Partners’s catalysts are its DARPin platform and oncology partnerships, plus any update that shows the platform can still produce meaningful partnering value.
Which conditions is Molecular Partners targeting with Molecular?
Molecular Partners is associated with oncology based on its company overview and current catalyst commentary.
How does Molecular Partners describe recent progress with Molecular?
Molecular Partners’s catalysts are its DARPin platform and oncology partnerships, plus any update that shows the platform can still produce meaningful partnering value.
What is Partners?
Molecular Partners is a biotechnology company focused on designed protein therapeutics and oncology.